Abstract
We report here the experience of the treatment with cetuximab in our department. Thirteen patients were treated with cetuximab. Median age was 65-year-old including 8 males and 5 females. Six cases were treated with single administration, and seven were with CPT-11. Median number of treatment was 13 times. In evaluable 9 cases, partial response (PR) was obtained in 3 cases and stable disease (SD) and progressive disease (PD) were in 2 and 4 cases, so that the response rate and disease control rate were 33% and 56%, respectively. Median survival after initiation of cetuximab was 219 days. Skin toxicity was observed in 91% including only one case with grade 3. We think that it is important to control skin toxicity for a continuation of cetuximab.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Cetuximab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Female
-
Humans
-
Irinotecan
-
Male
-
Middle Aged
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Irinotecan
-
Cetuximab
-
Camptothecin